Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNKS | O95271 | 4/20 | 0.61 |
| ▸ | BRD4 | O60885 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 3/20 | 0.39 |
| ▸ | HTR2C | P28335 | 3/20 | 0.39 |
| ▸ | HTR2B | P41595 | 2/20 | 0.39 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 1/20 | 0.36 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.34 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601664 | 0.87 | TNKS (0.58) | TNKSBRD4MAPK1KDM4EALDH1A1 | |
| SCHEMBL16456384 | 0.87 | TNKS (0.58) | TNKSBRD4MAPK1KDM4EALDH1A1 | |
| SCHEMBL16456006 | 0.82 | PKM (0.46) | TNKSBRD4MAPK1CALCRLPKM | |
| SCHEMBL3599617 | 0.81 | TNKS (0.55) | TNKSKDM4EALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL16444848 | 0.77 | TNKS (1.00) | TNKS | |
| SCHEMBL15289104 | 0.77 | TNKS (1.00) | TNKS | |
| SCHEMBL16444847 | 0.77 | TNKS (1.00) | TNKS | |
| SCHEMBL13884718 | 0.75 | TNKS (0.46) | TNKSMAPK1KDM4EALDH1A1MAPT | |
| SCHEMBL2872824 | 0.69 | BRD4 (0.56) | BRD4CALCRL | |
| SCHEMBL3603875 | 0.69 | BRD4 (0.55) | TNKSBRD4MAPK1CALCRLPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9340549-B2 | Oxazolidinone compounds and derivatives thereof | AMGEN INC. (US) | 2016-05-17 | — | — | US | disclosed |
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | AMGEN INC. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045368-A1 | OXAZOLIDINONE COMPOUNDS AND DERIVATIVES THEREOF | TNKS1BP1, TNKS, TBKBP1 | TNKS 2/4885BRD4 1444/4885MAPK1 1337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.